Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF fusion||low grade glioma||predicted - sensitive||Tovorafenib||Phase II||Actionable||In a Phase II trial (FIREFLY-1), Tovorafenib (MLN2480) treatment was well-tolerated and resulted in an overall response rate of 64% (44/69, 3 complete responses, 41 partial responses (10 unconfirmed)) and a clinical benefit rate of 91% in pediatric patients with low-grade glioma harboring BRAF fusions (n=64) or BRAF V600E (n=13) (J Clin Oncol 41, 2023 (suppl 16; abstr 10004); NCT04775485).||detail...|
|PubMed Id||Reference Title||Details|
|Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study||Full reference...|